SCHEMBL2845596

SCHEMBL2845596

COC=C1CC2(CCN(C(=O)OCc3ccccc3)CC2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
ENPP2 Q13822 2/20 0.48
ATXN2 Q99700 2/20 0.48
CYP2C19 P33261 3/20 0.48
HTT P42858 1/20 0.47
SCN5A Q14524 1/20 0.46
SCN9A Q15858 1/20 0.46
ALDH1A1 P00352 3/20 0.46
CYP2D6 P10635 2/20 0.46
OPRD1 P41143 1/20 0.45
OPRK1 P41145 1/20 0.45
KDM1A O60341 1/20 0.45
CYP3A4 P08684 4/20 0.44
MAPK1 P28482 2/20 0.44
HDAC3 O15379 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27194542 0.88 MEN1 (0.47) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL22284351 0.86 SMN1; SMN2 (0.50) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL25547613 0.84 MEN1 (0.49) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL9572627 0.84 MEN1 (0.57) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL30729332 0.83 MEN1 (0.49) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL15635814 0.83 F13A1 (0.49) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL2674601 0.82 MEN1 (0.58) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL934263 0.82 MEN1 (0.64) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL16969210 0.81 MEN1 (0.57) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL30746157 0.81 ENPP2 (0.46) MEN1KMT2ANPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526196-B1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS MERCK SHARP & DOHME LLC (US) 2026-03-18 EP disclosed
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENT OF THE UNIV OF MICHIGAN (US) 2026-01-29 US disclosed
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS UNIV MICHIGAN (US) 2026-01-08 US disclosed
US-20260000676-A1 CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS UNIV MICHIGAN REGENTS (US) 2026-01-01 US disclosed
WO-2025106472-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2025-05-22 WO disclosed
WO-2025106482-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2025-05-22 WO disclosed
WO-2025106480-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2025-05-22 WO disclosed
EP-4554948-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS Regents of the University of Michigan (US) 2025-05-21 EP disclosed
WO-2024015406-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-01-18 WO disclosed
WO-2024015408-A1 INDAZOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS REGENTS OF THE UNIVESITY OF MICHIGAN (US) 2024-01-18 WO disclosed
EP-2903985-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF Advinus Therapeutics Limited (IN) 2015-08-12 EP disclosed
US-20150218187-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD. (IN) 2015-08-06 US disclosed
US-20150218187-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD. (IN) 2015-08-06 US disclosed
US-20150218187-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD. (IN) 2015-08-06 US disclosed
WO-2014054053-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF ADVINUS THERAPEUTICS LIMITED (IN) 2014-04-10 WO disclosed
WO-2010062245-A1 SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2010-06-03 WO disclosed
WO-2010062245-A1 SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2010-06-03 WO disclosed
US-20100130477-A1 Spirocyclobutyl Piperidine Derivatives ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130477-A1 Spirocyclobutyl Piperidine Derivatives ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130477-A1 Spirocyclobutyl Piperidine Derivatives ASTRAZENECA AB (SE) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218187-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF DGAT1, DGAT2, CPT1A MEN1 2640/4885KMT2A 2800/4885NPSR1 2678/4885
US-20260028354-A1 TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB MEN1 3661/4885KMT2A 2018/4885NPSR1 75/4885
US-20260000676-A1 CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB MEN1 3970/4885KMT2A 1831/4885NPSR1 63/4885
US-20100130477-A1 Spirocyclobutyl Piperidine Derivatives HRH3, HRH4, HRH2 MEN1 2224/4885KMT2A 521/4885NPSR1 72/4885
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, AR MEN1 3918/4885KMT2A 1708/4885NPSR1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.